Component

C. zeylanicum standardized extract in the 2025 LDL trial

C. zeylanicum standardized extract in the 2025 LDL trial. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Fasting glucose reduction favored extract by an adjusted 8.59 mg/dL, 95% CI 0.59–16.59, p=0.036, on the secondary endpoint.

    C. zeylanicum standardized extract in the 2025 LDL trial → Serum glucose concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/39854533.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443", "start_char": 0, "end_char": 2414, "text_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443"}
    experimental_model
    Double-blind placebo-controlled randomized trial, complete-case analysis
    exposure
    150 randomized, 127 assessed at 12 weeks; standardized extract 1000 mg/day
    limitations
    LDL was primary and nonsignificant; fasting glucose was secondary. Missing follow-up, baseline metabolic status and preparation constrain generalization.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    The trial found a modest fasting-glucose signal, even though its main cholesterol result was negative.
    primary_references
    [ceylon-p39854533] Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. (2025). https://pubmed.ncbi.nlm.nih.gov/39854533/ DOI: 10.1371/journal.pone.0317904
    tissue_or_cell_type
    Adults with LDL-C 100–190 mg/dL

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1156–1167

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind placebo-controlled randomized trial, complete-case analysis · source_derived_draft · unverified_draft

    ### ceylon-trial-glucose Fasting glucose reduction favored extract by an adjusted 8.59 mg/dL, 95% CI 0.59–16.59, p=0.036, on the secondary endpoint. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial found a modest fasting-glucose signal, even though its main cholesterol result was negative. organism: Human tissue_or_cell_type: Adults with LDL-C 100–190 mg/dL experimental_model: Double-blind placebo-controlled randomized trial, complete-case analysis limitations: LDL was primary and nonsignificant; fasting glucose was secondary. Missing follow-up, baseline metabolic status and preparation constrain generalization. exposure: 150 randomized, 127 assessed at 12 weeks; standardized extract 1000 mg/day evidence_span: {"source_cache": "artifacts/ceylon-research/39854533.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443", "start_char": 0, "end_char": 2414, "text_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443"} [ceylon-p39854533] Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. (2025). https://pubmed.ncbi.nlm.nih.gov/39854533/ DOI: 10.1371/journal.pone.0317904
    Complete structured claim and evidence

  2. The trial did not find significant LDL lowering: baseline-adjusted between-group difference reported as 6.05 mg/dL, 95% CI −2.43 to 14.52, p=0.161.

    C. zeylanicum standardized extract in the 2025 LDL trial → LDL cholesterol concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/39854533.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443", "start_char": 0, "end_char": 2414, "text_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443"}
    experimental_model
    Double-blind placebo-controlled randomized trial, complete-case analysis
    exposure
    150 randomized, 127 assessed at 12 weeks; standardized extract 1000 mg/day
    limitations
    LDL was primary and nonsignificant; fasting glucose was secondary. Missing follow-up, baseline metabolic status and preparation constrain generalization.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    The main cholesterol endpoint did not show a reliable treatment benefit.
    primary_references
    [ceylon-p39854533] Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. (2025). https://pubmed.ncbi.nlm.nih.gov/39854533/ DOI: 10.1371/journal.pone.0317904
    tissue_or_cell_type
    Adults with LDL-C 100–190 mg/dL

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1143–1154

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind placebo-controlled randomized trial, complete-case analysis · source_derived_draft · unverified_draft

    ### ceylon-trial-ldl-null The trial did not find significant LDL lowering: baseline-adjusted between-group difference reported as 6.05 mg/dL, 95% CI −2.43 to 14.52, p=0.161. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The main cholesterol endpoint did not show a reliable treatment benefit. organism: Human tissue_or_cell_type: Adults with LDL-C 100–190 mg/dL experimental_model: Double-blind placebo-controlled randomized trial, complete-case analysis limitations: LDL was primary and nonsignificant; fasting glucose was secondary. Missing follow-up, baseline metabolic status and preparation constrain generalization. exposure: 150 randomized, 127 assessed at 12 weeks; standardized extract 1000 mg/day evidence_span: {"source_cache": "artifacts/ceylon-research/39854533.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443", "start_char": 0, "end_char": 2414, "text_sha256": "5a891f5ed9907674aa119b8c697d009c06017b11d7e21e7959013853e3fd3443"} [ceylon-p39854533] Effects of Cinnamomum zeylanicum (Ceylon cinnamon) extract on lipid profile, glucose levels and its safety in adults: A randomized, double-blind, controlled trial. (2025). https://pubmed.ncbi.nlm.nih.gov/39854533/ DOI: 10.1371/journal.pone.0317904
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards